Celularity Inc (CELU): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Celularity Inc (CELU) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001752828 0001752828 2026-06-19 2026-06-19 0001752828 CELU:ClassCommonStock0.0001ParValuePerShareMember 2026-06-19 2026-06-19 0001752828 CELU:WarrantsEachExercisableForOnetenthOfOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2026-06-19 2026-06-19 iso4217:US
How this was made
The 30-second read
Why it matters
The 8-K discloses leadership changes: Steven N. Gordon appointed COO & Administrative Officer and also elected to the board; K. Harold Fletcher appointed Chief Legal and Strategy Officer and Corporate Secretary. Compensation is deferred to later filings if required.
Market read
This is a governance/leadership update without disclosed financial terms, so it is more of a monitoring catalyst than an immediate trading driver.
What to watch
Traders should watch subsequent filings for compensation details, restructuring/financing actions, or board/strategic committee changes that could make this appointment material.
Background
The company filed an SEC Form 8-K (Item 5.02) reporting board/officer appointments effective June 19, 2026.
Ticker impact
Celularity appointed Steven N. Gordon as Chief Operating and Administrative Officer and K. Harold Fletcher as Chief Legal and Strategy Officer effective June 19, 2026.
Likely limited near-term impact unless followed by material financing, restructuring, or clinical/strategic updates in later filings.
The filing is a routine 8-K for officer/director appointments; it does not include compensation amounts, transactions, or operational milestones beyond role changes.
Market effects
Biotech governance/operations reshuffles can precede financing or restructuring, but this filing provides no sector-wide datapoint.
None indicated.
None indicated.
Counterpoint
Officer changes may be largely administrative (no disclosed compensation/transactions), so price may ignore it absent follow-on catalysts.
Key entities
- companyCelularity Inc
Nasdaq-listed biotech company filing Item 5.02 8-K for officer/director appointments.
- officer/directorSteven N. Gordon, Esq.
Appointed Chief Operating and Administrative Officer; elected to the board effective June 19, 2026.
- officerK. Harold Fletcher, Esq.
Appointed Chief Legal and Strategy Officer and Corporate Secretary effective June 19, 2026.



